A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controlled focal seizures.

Trial Profile

A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controlled focal seizures.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Cannabidivarin (Primary)
  • Indications Partial epilepsies
  • Focus Pharmacokinetics
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 02 Jun 2016 Status changed from recruiting to completed.
    • 06 Apr 2015 New source identified and integrated (United Kingdom Clinical Research Network: 17660)
    • 28 Mar 2015 Status changed from planning to recruiting as per EU Clinical Trials Register record .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top